Vaccination News Home Page

http://www.sciencedirect.com/science?_ob=IssueURL&_tockey=%23TOC%235188%232002%23999789996%23365446%23FLA%23Volume_21,_Issues_3-4,_Pages_155-329_(13_December_2002)&_auth=y&wchp=dGLbVzz-lSzBV&_acct=C000050221&_version=1&_urlVersion=0&_userid=10&md5=f97a214c2ee2beee1ff9485a8b73fc0e

Go to ScienceDirect Home Skip Main Navigation Links
 Register or Login:   Password:     Athens Login 
HomeBrowse JournalsBrowse Abstract DatabasesBrowse Reference WorksMy AlertsMy Profile Help (Opens new window)
Issues
Vaccine
Copyright © 2002 Elsevier Science Ltd. All rights reserved

Volume 21, Issues 3-4,
Pages 155-329 (13 December 2002)
   
E-mail Articles
        Selected checked docs: display checked docs
1.
Longevity of neutralizing antibody levels in macaques vaccinated with Quil A-adjuvanted measles vaccine candidates, Pages 155-157
Koert J. Stittelaar, Helma W. Vos, Geert van Amerongen, Gideon F. A. Kersten, Albert D. M. E. Osterhaus and Rik L. de Swart
Abstract | Full Text + Links | PDF (68 K)
2.
Combined intrarectal/intradermal inoculation of recombinant Mycobacterium bovis bacillus Calmette–Guérin (BCG) induces enhanced immune responses against the inserted HIV-1 V3 antigen, Pages 158-166
Mamoru Kawahara, Kazuhiro Matsuo, Tadashi Nakasone, Takachika Hiroi, Hiroshi Kiyono, Sohkichi Matsumoto, Takeshi Yamada, Naoki Yamamoto and Mitsuo Honda
Abstract | Full Text + Links | PDF (269 K)
3.
Candidate peptide vaccine induced protection against classical swine fever virus, Pages 167-173
Xiao-Nan Dong, Ke Wei, Zu-Qiang Liu and Ying-Hua Chen
Abstract | Full Text + Links | PDF (112 K)
4.
The role of BCG in human immune responses induced by multiple injections of autoclaved Leishmania major as a candidate vaccine against leishmaniasis, Pages 174-180
Mohammad Hossein Alimohammadian, Ali Khamesipour, Haiedeh Darabi, Alireza Firooz, Shirin Malekzadeh, Ahmad Bahonar, Yahya Dowlati and Farrokh Modabber
Abstract | Full Text + Links | PDF (133 K)
5.
Post-licensure comparative study of unusual high-pitched crying and prolonged crying following COMVAX(TM) and placebo versus PedvaxHIB(TM) and RECOMBIVAX HB(TM) in healthy infants, Pages 181-187
Karen M. Kaplan, Steven A. Rusche, Hassan D. Lakkis, Gerald Bottenfield, Fernando A. Guerra, Juan Guerrero, Harry Keyserling, Elise Felicione, Teresa M. Hesley and John W. Boslego
Abstract | Full Text + Links | PDF (72 K)
6.
Comparative evaluation of a combined DTP–HB vaccine in the EPI in Chiangrai Province, Thailand, Pages 188-193
Supamit Chunsuttiwat, Beverley-Ann Biggs, James E. Maynard, Piyanit Thammapormpilas and Monthakarn O-Prasertsawat
Abstract | Full Text + Links | PDF (125 K)
7.
Safety and efficacy of E. coli enterotoxin adjuvant for urease-based rectal immunization against Helicobacter pylori, Pages 194-201
Stavros Sougioultzis, Cynthia K. Lee, Mazen Alsahli, Subhas Banerjee, Michel Cadoz, Robert Schrader, Bruno Guy, Philip Bedford, Thomas P. Monath, Ciaran P. Kelly and Pierre Michetti
Abstract | Full Text + Links | PDF (111 K)
8.
Vaccination with an adenoviral vector encoding hepatitis C virus (HCV) NS3 protein protects against infection with HCV-recombinant vaccinia virus, Pages 202-210
Laura Arribillaga, Ascensión López Díaz de Cerio, Pablo Sarobe, Noelia Casares, Marta Gorraiz, Africa Vales, Oscar Bruna-Romero, Francisco Borrás-Cuesta, Glaucia Paranhos-Baccala, Jesús Prieto et al.
Abstract | Full Text + Links | PDF (147 K)
9.
Induction of hepatitis C virus-specific cytotoxic T lymphocytes in mice by immunization with dendritic cells transduced with replication-defective recombinant adenovirus, Pages 211-220
Masanori Matsui, Osamu Moriya, Nada Abdel-Aziz, Yoshiharu Matsuura, Tatsuo Miyamura and Toshitaka Akatsuka
Abstract | Full Text + Links | PDF (245 K)
10.
A randomized, placebo-controlled trial of subcutaneous administration of GM-CSF as a vaccine adjuvant: effect on cellular and humoral immune responses, Pages 221-230
Jyoti Somani, Sagar Lonial, Hilary Rosenthal, Suzanne Resnick, Irina Kakhniashvili and Edmund K. Waller
Abstract | Full Text + Links | PDF (209 K)
11.
Infection of mouse bone marrow-derived dendritic cells with recombinant adenovirus vectors leads to presentation of encoded antigen by both MHC class I and class II molecules––potential benefits in vaccine design, Pages 231-242
Osquel Barroso Herrera, Sara Brett and Robert I. Lechler
Abstract | Full Text + Links | PDF (309 K)
12.
Antihepatitis B response to hepatitis B vaccine administered simultaneously with tetanus toxoid in nonresponder individuals, Pages 243-246
Emine Sönmez, Ali Suha Sönmez, YaImagear Bayindir, Diler Coskun and Sedat Aritürk
Abstract | Full Text + Links | PDF (53 K)
13.
DNA vaccination with linear minimalistic (MIDGE) vectors confers protection against Leishmania major infection in mice, Pages 247-257
L. López-Fuertes, E. Pérez-Jiménez, A. J. Vila-Coro, F. Sack, S. Moreno, S. A. Konig, C. Junghans, B. Wittig, M. Timón and M. Esteban
Abstract | Full Text + Links | PDF (319 K)
14.
Evaluation of FIV protein-expressing VEE-replicon vaccine vectors in cats, Pages 258-268
Mary Jo Burkhard, Loretta Valenski, Sarah Leavell, Gregg A. Dean and Wayne A. F. Tompkins
Abstract | Full Text + Links | PDF (243 K)
15.
Immediate-type hypersensitivity and other clinical reactions in volunteers immunized with a synthetic multi-antigen peptide vaccine (PfCS-MAP1NYU) against Plasmodium falciparum sporozoites, Pages 269-280
Robert Edelman, Steven S. Wasserman, James G. Kublin, Sacared A. Bodison, Elizabeth H. Nardin, Giane A. Oliveira, Sobia Ansari, Carter L. Diggs, Oscar L. Kashala, Barbara J. Schmeckpeper and Robert G. Hamilton
Abstract | Full Text + Links | PDF (179 K)
16.
Reactogenicity and immunogenicity of a live attenuated tetravalent measles–mumps–rubella–varicella (MMRV) vaccine, Pages 281-289
Terry Nolan, Peter McIntyre, Don Roberton and Dominique Descamps
Abstract | Full Text + Links | PDF (136 K)
17.
The generation and characterization of potentially therapeutic Asmall beta, Greek antibodies in mice: differences according to strain and immunization protocol, Pages 290-297
Edward T. Spooner, Roanak V. Desai, Chica Mori, Jodi F. Leverone and Cynthia A. Lemere
Abstract | Full Text + Links | PDF (297 K)
18.
The Brighton Collaboration: addressing the need for standardized case definitions of adverse events following immunization (AEFI), Pages 298-302
Jan Bonhoeffer, Katrin Kohl, Robert Chen, Philippe Duclos, Harald Heijbel, Ulrich Heininger, Tom Jefferson, Elisabeth Loupi and The Brighton Collaboration
Abstract | Full Text + Links | PDF (75 K)
19.
Comparing potential benefits of new pneumococcal vaccines with the current polysaccharide vaccine in the elderly, Pages 303-311
Alicia M. Fry, Elizabeth R. Zell, Anne Schuchat, Jay C. Butler and Cynthia G. Whitney
Abstract | Full Text + Links | PDF (123 K)
20.
Cost-effectiveness of hepatitis B vaccination of prison inmates, Pages 312-321
Maria Pisu, Martin Isaac Meltzer and Rob Lyerla
Abstract | Full Text + Links | PDF (139 K)
21.
The use of Flt3 ligand as an adjuvant for hepatitis B vaccination of healthy adults, Pages 322-329
Thomas G. Evans, Muhammad Hasan, Laurent Galibert and Dania Caron
Abstract | Full Text + Links | PDF (158 K)
22.
Editorial Board/Aims and Scope, Page CO2

PDF (43 K)


 

E-mail Articles
Issues
HomeBrowse JournalsBrowse Abstract DatabasesBrowse Reference WorksMy AlertsMy Profile   Help (Opens new window)


 

Send feedback to ScienceDirect
Software and compilation © 2002 ScienceDirect. All rights reserved.
ScienceDirect® is an Elsevier Science B.V. registered trademark.


Your use of this service is governed by Terms and Conditions. Please review our Privacy Policy for details on how we protect information that you supply.

 

Vaccination News Home Page

ALL INFORMATION, DATA, AND MATERIAL CONTAINED, PRESENTED, OR PROVIDED HERE IS FOR GENERAL INFORMATION PURPOSES ONLY AND IS NOT TO BE CONSTRUED AS REFLECTING THE KNOWLEDGE OR OPINIONS OF THE PUBLISHER, AND IS NOT TO BE CONSTRUED OR INTENDED AS PROVIDING MEDICAL OR LEGAL ADVICE.  THE DECISION WHETHER OR NOT TO VACCINATE IS AN IMPORTANT AND COMPLEX ISSUE AND SHOULD BE MADE BY YOU, AND YOU ALONE, IN CONSULTATION WITH YOUR HEALTH CARE PROVIDER.